Manufacturing systems need to meet I4.0 guidelines to deal with uncertainty in scenarios of turbulent demand for products. The engineering concepts to define the service’s resources to manufacture the products will be more flexible, ensuring the possibility of re-planning in operation. These can follow the engineering paradigm based on capabilities. The virtualization of industry components and assets achieves the RAMI 4.0 guidelines and (I4.0C), which describes the Asset Administration Shell (AAS). However, AAS are passive components that provide information about I4.0 assets. The proposal of specific paradigms is exposed for managing these components, as is the case of multi-agent systems (MAS) that attribute intelligence to objects. The implementation of resource coalitions with evolutionary architectures (EAS) applies cooperation and capabilities’ association. Therefore, this work focuses on designing a method for modeling the asset administration shell (AAS) as virtual elements orchestrating intelligent agents (MAS) that attribute cooperation and negotiation through contracts to coalitions based on the engineering capabilities concept. The systematic method suggested in this work is partitioned for the composition of objects, AAS elements, and activities that guarantee the relationship between entities. Finally, Production Flow Schema (PFS) refinements are applied to generate the final Petri net models (PN) and validate them with Snoopy simulations. The results achieved demonstrate the validation of the procedure, eliminating interlocking and enabling liveliness to integrate elements behavior.

Databases are by far the most valuable asset of companies. Since the need was seen not only to count but also to have some type of record of elements such as crops, animals, money, properties and that this record could be consulted and modified according to the situation, that is where the first database was born. , and after that, these databases cannot be disorganized, they also need to be managed and administered under established standards that facilitate their understanding and management not only by their creators but by the other people who subsequently administer them. Databases and database management systems have an interesting evolutionary history that deserves to be analyzed and this is the objective of this document, where it is sought to understand. Along with databases and their management systems, data mining or Data mining arises that in order not to extend ourselves so much, it is the job of finding common patterns in various data sources and in what way they can be used to predict situations or results of various circumstances; We also focus on the other topic that we will present, Oracle data mining, which roughly is to merge data mining with Oracle, which makes it a powerful tool for obtaining information and predicting results based on statistics.In this article we will study and analyze the ideas, concepts and basic examples that make up SGBD and Data Mining and, we will try to go deeper into this topic, the use of decision techniques such as advanced statistical algorithms. We also present a fictitious example of the application of these techniques: predicting which products can be sold based on their relationship with others. we will give a brief explanation of association rules, data mining cycle and the types of learning and the evolution that data mining has had.

The use of chimeric antigen receptors (CAR-T cells) for the treatment of patients with malignant haematological diseases has become a well-established application, for conditions such as refractory or relapsed B cell acute lymphoblastic leukaemia (B-ALL), B cell lymphomas (BCL), and multiple myeloma (MM). Nearly 35,000 patients have received autologous CAR-T cells for the treatment of these conditions only in the USA. Since their approval by the Food and Drug Administration (FDA) in 2017, over 1200 clinical trials have been initiated globally and there are at least 10 different CAR-T cells with approval by different regulatory agencies around the globe. In the USA the Food and Drug Administration (FDA) has approved 6 commercial CAR-T cells that are widely distributed worldwide. At the time of this writing, several clinical trials have been performed in patients with solid tumours such as glioblastoma, renal and pancreatic cancer, as well as in patients with autoimmune conditions such as systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SS). There are also several studies showing the potential benefit of CAR-T cells for other non-malignant diseases such as asthma and even fungal infections. In this review, without pretending to cover all the current areas of treatments with CAR-T cells, we offer a brief summary of some of the most relevant aspects of the use of CAR-T cells for some of these conditions.